Vardenafil — Membership Pricing
Vardenafil is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Vardenafil Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $110.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Vardenafil
Vardenafil is a prescription medication. Ask your doctor if Vardenafil is right for you.
Conditions Treated with Vardenafil
How to Check Vardenafil Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Vardenafil at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Erectile Dysfunction
Other medications in Urology
What Vardenafil is approved for (FDA label)
Vardenafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction. ( 1 ) Vardenafil tablets are indicated for the treatment of erectile dysfunction.
Source: Read the full FDA label on DailyMed. Label effective date: January 5, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Vardenafil (FDA label)
Vardenafil tablets USP, 2.5 mg (equivalent to 2.963 mg vardenafil hydrochloride trihydrate), 5 mg (equivalent to 5.926 mg vardenafil hydrochloride trihydrate), 10 mg (equivalent to 11.852 mg vardenafil hydrochloride trihydrate), 20 mg (equivalent to 23.705 mg vardenafil hydrochloride trihydrate) ( 3 ) Vardenafil tablets, USP are available as 2.5 mg (equivalent to 2.963 mg vardenafil hydrochloride), 5 mg (equivalent to 5.926 mg vardenafil hydrochloride), 10 mg (equivalent to 11.852 mg vardenafil hydrochloride), 20 mg (equivalent to 23.705 mg vardenafil hydrochloride). Vardenafil tablets, 2.5 mg are white to off-white colored, round, biconvex, bevel edged, film-coated tablets, debossed with "10" on one side and "68" on other side.
Source: FDA prescribing information (DailyMed). Set ID: 5876e062-e604-42a7-99c3-5da30b8dac06. SPL document ID: a6417d62-c65a-49a5-a3c7-d9d178a36cb9. Label effective date: January 5, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Vardenafil (FDA label)
Most common adverse reactions reported ( ≥ 2% of patients) are headache, flushing, nasal congestion, dyspepsia, sinusitis, flu syndrome, dizziness, increased creatine kinase, nausea, back pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Source: FDA prescribing information (DailyMed). Set ID: 5876e062-e604-42a7-99c3-5da30b8dac06. SPL document ID: a6417d62-c65a-49a5-a3c7-d9d178a36cb9. Label effective date: January 5, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Vardenafil (FDA label)
Administration with nitrates and nitric oxide donors ( 2.4 , 4.1 ) Administration with guanylate cyclase (GC) stimulators, such as riociguat ( 2.4 , 4.2 ) 4.1 Nitrates Administration of vardenafil with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see Clinical Pharmacology ( 12.2 )] . Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors, including vardenafil, may potentiate the hypotensive effects of nitrates. A suitable time interval following dosing of vardenafil for the safe administration of nitrates or nitric oxide donors has not been determined. 4.2 Guanylate Cyclase (GC) Stimulators Do not use vardenafil in patients who are using a GC stimulator, such as riociguat. PDE5 inhibitors, including vardenafil may potentiate the hypotensive effects of GC stimulators.
Source: FDA prescribing information (DailyMed). Set ID: 5876e062-e604-42a7-99c3-5da30b8dac06. SPL document ID: a6417d62-c65a-49a5-a3c7-d9d178a36cb9. Label effective date: January 5, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Vardenafil (FDA label)
Cardiovascular Effects : Patients should not use vardenafil if sex is inadvisable due to cardiovascular status. ( 5.1 ) Risk of Priapism : In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance. ( 5.3 ) Effects on the Eye : Patients should stop use of vardenafil, and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of nonarteritic anterior ischemic optic neuropathy (NAION).
Source: FDA prescribing information (DailyMed). Set ID: 5876e062-e604-42a7-99c3-5da30b8dac06. SPL document ID: a6417d62-c65a-49a5-a3c7-d9d178a36cb9. Label effective date: January 5, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Vardenafil (FDA label)
Vardenafil can potentiate the hypotensive effects of nitrates, alpha-blockers, and antihypertensives. ( 7.1 ) 7.1 Potential for Pharmacodynamic Interactions with Vardenafil Nitrates Concomitant use of vardenafil and nitrates and nitric oxide donors is contraindicated. The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours after vardenafil were potentiated by a 20 mg dose of vardenafil in healthy middle-aged subjects. These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG). Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of vardenafil and nitrates is contraindicated [see Contraindications ( 4.1 ) and Clinical Pharmacology ( 12.2 ) . Alpha-Blockers Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.
Source: FDA prescribing information (DailyMed). Set ID: 5876e062-e604-42a7-99c3-5da30b8dac06. SPL document ID: a6417d62-c65a-49a5-a3c7-d9d178a36cb9. Label effective date: January 5, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.